Glider - GLPG3970-CL-207

• Research type

  Research Study

• Full title

  A randomized, double-blind, placebo-controlled, multicenter study to\nevaluate the efficacy, safety, tolerability, pharmacokinetics, and\npharmacodynamics of orally administered GLPG3970 for 12 weeks in\nadult subjects with active primary Sjögren’s Syndrome

• IRAS ID

  274293

• Contact name

  Benjamin Fisher

• Contact email

  B.Fisher@bham.ac.uk

• Sponsor organisation

  Galapagos NV

• Eudract number

  2020-003298-22

• Duration of Study in the UK

  0 years, 11 months, 17 days

• Research summary

  The study evaluating the effects of GLPG3970 given as an oral treatment for 12 weeks in adults with active primary Sjögren’s Syndrome. The study is planned to randomize 30 adult subjects in a 2:1 ratio (20 subjects planned to\nreceive GLPG3970 and 10 subjects planned to receive placebo).The subjects will be in the study for a duration of 18 weeks: up to 4 weeks of screening,\n12 weeks of treatment, and 2 weeks of FU.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  20/NW/0468

• Date of REC Opinion

  3 Feb 2021

• REC opinion

  Further Information Favourable Opinion